{"id":5,"date":"2024-03-15T13:07:59","date_gmt":"2024-03-15T04:07:59","guid":{"rendered":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/?p=5"},"modified":"2024-03-17T07:37:47","modified_gmt":"2024-03-16T22:37:47","slug":"achieve","status":"publish","type":"post","link":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/achievement\/achieve\/","title":{"rendered":"\u4e73\u817a\u5185\u5206\u6ccc\u5916\u79d1\u30b9\u30bf\u30c3\u30d5\u306e\u4e3b\u306a\u696d\u7e3e"},"content":{"rendered":"
\n
\n
\n
\n

Breast Cancer \u3000 2024 Mar;31(2<\/span><\/span><\/span>;31(2):234-242.<\/span><\/strong><\/h4>\n<\/div>\n

Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale<\/span><\/p>\n

Yosuke Aoyama\u00a0<\/span>1<\/sup>,\u00a0<\/span><\/span>Eri Hoshino\u00a0<\/span>2<\/sup>,\u00a0<\/span><\/span>Akihiko Shimomura\u00a0<\/span>3<\/sup>,\u00a0<\/span><\/span>Chikako Shimizu\u00a0<\/span>3<\/sup>,\u00a0<\/span><\/span>Tomoko Taniyama\u00a0<\/span>3<\/sup>,\u00a0<\/span><\/span>Manami Tada\u00a0<\/span>4<\/sup>,\u00a0<\/span><\/span>Nao Yoshida\u00a0<\/span>4<\/sup>,\u00a0<\/span><\/span>Hitomi Sato\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Kiyomi Nonogaki\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Kazumasa Yamamoto\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Taro Yamanaka\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Rika Kizawa\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Takeshi Yamaguchi\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Kiyo Tanaka\u00a0<\/span>6<\/sup>,\u00a0<\/span><\/span>Yoko Kobayashi\u00a0<\/span>6<\/sup>,\u00a0<\/span><\/span>Nobuko Tamura\u00a0<\/span>6<\/sup>,\u00a0<\/span><\/span>Yuko Tanabe\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Yuji Miura\u00a0<\/span>5<\/sup>,\u00a0<\/span><\/span>Yuichiro Kikawa\u00a0<\/span>4<\/sup>,\u00a0<\/span><\/span>Juhee Cho\u00a0<\/span>7<\/sup>,\u00a0<\/span><\/span>Hidetaka Kawabata\u00a0<\/span>6<\/sup><\/span><\/span><\/p>\n

Jpn J Clin Oncol. 2023 Jun 29;53(7):562-571<\/span><\/h4>\n

Effectiveness of PET\/CT and VATS for detecting and treating internal mammary lymph node metastasis: A case series<\/span><\/p>\n

Shun Kawaguchi1*<\/sup>, Nobuko Tamura1<\/sup>, Soichiro Suzuki2<\/sup>, Aya Nishikawa1<\/sup>, Akio Shibata1<\/sup>, Kiyo Tanaka1<\/sup>, Yoko Kobayashi1<\/sup>, Takuya Ogura1<\/sup>, Junichiro Sato3<\/sup>, Keiichi Kinowaki3<\/sup>, Masato Shiiba4<\/sup>, Makiko Ishihara4<\/sup>, Sakashi Fujimori2<\/sup> and Hidetaka Kawabata1<\/sup><\/span><\/p>\n<\/div>\n<\/div>\n

\n

Breast Cancer. 2023 Jul;30(4):637-646.<\/span><\/h4>\n

High-Accuracy Prediction of Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma using Focal Cortical Thickening on Magnetic Resonance Imaging <\/span><\/p>\n

Shun Kawaguchia*<\/sup>,\u00a0Keiichi Kinowakib<\/sup>,\u00a0Nobuko Tamuraa<\/sup>, Tomohiko Masumotoc<\/sup>,\u00a0Aya Nishikawaa<\/sup>, Akio Shibataa<\/sup>, Kiyo Tanakaa<\/sup>,\u00a0Yoko Kobayashia<\/sup>, Takuya Oguraa<\/sup>,\u00a0Junichiro Satob<\/sup> and\u00a0Hidetaka Kawabataa<\/sup><\/span><\/p>\n<\/div>\n

\n
\n
\n

Am J Cancer Res .\u00a0<\/span>2023 Oct 15;13(10):4931-4943<\/span><\/span><\/h4>\n<\/div>\n

IL25+ macrophages are a key determinant of treatment resistance of IL17RB+ breast cancer<\/span><\/p>\n

Yukinori Ozaki,1,<\/sup>2,<\/sup>3<\/sup>\u00a0Keiichi Kinowaki,4<\/sup>\u00a0Hidetaka Kawabata,5<\/sup>\u00a0and\u00a0Chie Kudo-Saito1<\/sup><\/span><\/p>\n

J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136\/jitc-2023-007126.<\/strong><\/span><\/h4>\n

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).<\/span><\/p>\n

Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T.<\/span><\/p>\n

Front Oncol\u00a0 2022: 12: 989650<\/span><\/strong><\/h4>\n

Clinical prediction model based on 18F-FDG PET\/CT plus contrast-enhanced MRI for axillary lymph node macrometastasis.<\/a><\/span><\/p>\n

Kawaguchi S, Tamura N, Tanaka K, Kobayashi Y, Sato J, Kinowaki K, Shiiba M, Ishihara M,\u00a0Kawabata H.<\/span><\/p>\n<\/div>\n

Cells. 2022 Nov 15;11(22):3610.<\/span><\/h4>\n

Estrogen-Inducible LncRNA\u00a0BNAT1<\/em>\u00a0Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells.<\/a><\/span><\/p>\n

Horie K, Takagi K, Takeiwa T, Mitobe Y,\u00a0Kawabata H, Suzuki T, Ikeda K, Inoue S.<\/span><\/div>\n
\n

Sci Rep. 2022 Jun 9;12(1):9495. doi: 10.1038\/s41598-022-13601-7.<\/span><\/h4>\n<\/div>\n<\/div>\n
\n
\n

PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2.<\/span><\/a><\/p>\n

Takeiwa T, Ikeda K, Suzuki T, Sato W, Iino K, Mitobe Y,\u00a0Kawabata H, Horie K, Inoue S.\u00a0<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

Pathol Int. 2022 Feb;72(2):96-106. doi: 10.1111\/pin.13190. Epub 2021 Dec 8.<\/span><\/h4>\n

TRIM39 is a poor prognostic factor for patients with estrogen receptor-positive breast cancer and promotes cell cycle progression.<\/span><\/p>\n

Ogura T, Azuma K, Takeiwa T, Sato J, Kinowaki K, Ikeda K,\u00a0Kawabata H, Inoue S.<\/span><\/div>\n

Eur J Cancer. 2022 Aug;171:193-202.\u00a0<\/span><\/h4>\n
\n

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).<\/span><\/p>\n

Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y,\u00a0Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T.<\/span><\/div>\n<\/div>\n
\n

Medicine (Baltimore). 2022 Dec 16;101(50):e32199. doi: 10.1097\/\u00a0\u00a0<\/strong><\/span>PMID: 36550858\u00a0 \u00a0\u00a0<\/strong><\/span><\/h4>\n

Solitary fibrous tumor of male breast: A case report and literature review<\/span><\/p>\n

Kawaguchi S, Kinowaki K, Tamura N, Nishikawa A, Shibata A, Tanaka K, Kobayashi Y, Ogura T, Sato J, Kawabata H.<\/span><\/p>\n<\/div>\n

\n
\n
\n

Int J Mol Sci.\u00a0 2021, 22, 11505. https:\/\/doi.org\/10.3390\/ijms222111505<\/span><\/h4>\n

OCT1 is a poor prognostic factor for breast cancer patients and promotes cell proliferation via inducing NCAPH<\/span><\/p>\n

Takuya\u00a0Ogura, Kotaro Azuma, Junichiro Sato, Keiichi Kinowaki, Ken-Ichi Takayama, Toshihiko Takeiwa, Hidetaka Kawabata, Satoshi\u00a0Inoue<\/span><\/p>\n

Breast Cancer Res Treat. 2021 Dec;190(3):425-434.\u00a0<\/span><\/h4>\n

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)<\/span><\/p>\n

Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M,\u00a0Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda N.<\/span><\/p>\n

Breast Cancer Res Treat. 2021 Jul;188(1):117-131<\/span><\/h4>\n

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial<\/span><\/p>\n

Norikazu Masuda, Hiroko Bando, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori E. Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R. Kataoka, Ryuji Uozumi, Shinji Ohno & Masakazu Toi<\/span><\/p>\n

Pathol Int\u3000\u00a02021 Jan;71(1):60-69<\/span><\/h4>\n

Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population<\/span><\/p>\n

Junichiro Sato, Kotaro Azuma, Keiichi Kinowaki, Kazuhiro Ikeda, Takuya Ogura, Yutaka Takazawa , Hidetaka Kawabata, Masanobu Kitagawa, Satoshi Inoue<\/span><\/p>\n

Clin Breast Cancer. 2021 Oct;21(5):399-407<\/span><\/h4>\n

Combined Use of Immunoreactivities of RIG-I with Efp\/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer<\/span><\/p>\n

Junichiro Sato,\u00a0Kotaro Azuma\u00a0Keiichi Kinowaki,\u00a0Kazuhiro Ikeda,\u00a0Takuya Ogura,\u00a0YutakaTakazawa,\u00a0Hidetaka Kawabata,\u00a0Masanobu Kitagawa,\u00a0Satoshi Inoue<\/span><\/p>\n

Breast Cancer. 2021 Jul;28(4):896-903<\/span><\/h4>\n

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.<\/span><\/p>\n

Tanaka K, Masuda N, Hayashi N, Sagara Y, Hara F, Kadoya T, Matsui A, Miyazaki C, Shien T, Tokunaga E, Hayashi T, Niikura N, Maeda S, Komoike Y, Bando H, Kanbayashi C, Iwata H.<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

Cancer Res. 2020 Jun 1;80(11):2230-2242.<\/span><\/h4>\n

PSF promotes ER-positive breast cancer progression via posttranscriptional regulation of ESR1 and SCFD2<\/span><\/span>
\nYuichi Mitobe, Kaori Iino, Ken-ichi Takayama, Kazuhiro Ikeda, Takashi Suzuki, Kenjiro Aogi, Hidetaka Kawabata, Yutaka Suzuki, Kuniko Horie-Inoue and Satoshi Inoue<\/span><\/span><\/p>\n

BMC Cancer\u00a0 \u00a0 \u00a0\u00a0<\/span>2020 Apr 16;20(1):325.\u00a0<\/span>doi: 10.1186\/s12885-020-06834-0.<\/span><\/span><\/h4>\n

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients<\/span>
\nYuko Tanabe; Seiji Shiraishi; Kenji Hashimoto; Kazutaka Ikeda; Daisuke Nishizawa; Junko Hasegawa; Akihiko Shimomura; Yukinori Ozaki; Nobuko Tamura; Mayu Yunokawa; Kan Yonemori; Toshimi Takano; Hidetaka Kawabata; Kenji Tamura; Yasuhiro Fujiwara; Chikako Shimizu<\/span><\/p>\n

Cancer Sci.\u00a0 \u00a0 \u00a0 2019 Nov 16. doi: 10.1111\/cas.14240. [Epub ahead of print]<\/span><\/h4>\n

RNA-binding protein NONO promotes breast cancer proliferation via posttranscriptional regulation of SKP2 and E2F8<\/span>
\nIino, Kaori; Mitobe, Yuichi; Ikeda, Kazuhiro; Takayama, Kenichi; Suzuki, Takashi; Kawabata, Hidetaka; Suzuki, Yutaka; Horie-Inoue, Kuniko; Inoue, Satoshi<\/span><\/p>\n

Mol Cell Biol.\u00a0 \u00a0 \u00a0 2019 Nov 12;39(23). pii: e00261-19. doi: 10.1128\/MCB.00261-19. Print 2019 Dec 1.<\/span><\/h4>\n

ESR1-stabilizing lncRNA TMPO-AS1 promotes hormone-refractory breast cancer progression. <\/span>
\nYuichi Mitobea , Kazuhiro Ikeda , Takashi Suzuki , Kiyoshi Takagi , Hidetaka Kawabata , Kuniko Horie-Inoue and Satoshi Inoue<\/span><\/p>\n

BMC Cancer.\u00a0 \u00a0 \u00a02019 Oct 22;19(1):980.<\/span><\/h4>\n

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review<\/span><\/p>\n

Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi & Toshimi Takano<\/span><\/p>\n

Breast.\u00a0 \u00a0 \u00a02018 Apr 23;40:67-75<\/span><\/h4>\n

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B\/ELTOP.<\/span>
\nTakano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.<\/span><\/p>\n

Asia Pac J Clin Oncol.\u00a0 \u00a0 \u00a02018 Mar 1. doi: 10.1111\/ajco.12863<\/span><\/h4>\n

A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.<\/span>
\nKikuchi Y, Uchida Y, Shirakawa K, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Sugiura R, Kawabata H, Seto Y, Ogawa T.<\/span><\/p>\n

Breast Cancer.\u00a0 \u00a0 \u00a02018 May;25(3):343-349<\/span><\/h4>\n

Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.<\/span>
\nOzaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T.<\/span><\/p>\n

Int J Mol Sci.\u00a0 \u00a0 \u00a0 2017 Sep 8;18(9). pii: E1931.<\/span><\/h4>\n

Hidetaka Kawabata, Kotaro Azuma, Kazuhiro Ikeda, Ikuko Sugitani, Keiichi Kinowaki, Takeshi Fujii, Akihiko Osaki, Toshiaki Saeki, Kuniko Horie-Inoue, Satoshi Inoue<\/span>
\nTRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-\u03baB signaling<\/span><\/p>\n

Cancer Chemother Pharmacol.\u00a0 \u00a0 \u00a02017 Jun;79(6):1179-1186<\/span><\/h4>\n

Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y.<\/span>
\nPaclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.<\/span><\/p>\n

Breast Cancer Res Treat.\u00a0 \u00a0 2014 May;145(1):143-53<\/span><\/h4>\n

Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.<\/span>
\nSurvival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).<\/span><\/p>\n

The Breast 2014\u00a0 \u00a0 \u00a0August 23(4) 466-72<\/span><\/h4>\n

Maki Tanioka, Masaoki Sasaki, Akihiko Shimomura, Makoto Fujishima, Mihoko Doi, Kazuo Matsuura, Toshiko Sakuma, Kenichi Yoshimura, Toshiaki Saeki, Masahiro Ohara, Junji Tsurutani,Masahiro Watatani, Toshimi Takano, Hidetaka Kawabata, Hirofumi Mukai, Yoichi Naito, Koichi Hirokaga, Shintaro Takao and Hironobu Minami<\/span>
\nPathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status<\/span><\/p>\n

Chemotherapy\u00a0 \u00a0 2013; 59(2):93-98<\/span><\/h4>\n

Marie Hanaoka, Hidetaka Kawabata, Tsuguo Iwatani, Toshimi Takano, Daishu Miura Reduction of Toxicity by Reversing the Order of Infusion of Docetaxel and Cyclophosphamide.<\/span><\/p>\n

J Cancer\u00a0 \u00a0 \u00a02013 4:519-523<\/span><\/h4>\n

Miura Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, and Takano T:<\/span>
\nThe safety of chemotherapy for breast cancer patients with hepatitis C virus infection.<\/span><\/p>\n

Psycho-Oncology 2012 (Article first published online:DOI: 10.1002\/pon.3023)<\/span><\/h4>\n

Tsuguo Iwatani, Ayako Matsuda, Hidetaka Kawabata, Daishu Miura, Eisuke Matsushima<\/span>
\nPredictive factors for psychological distress related to diagnosis of breast cancer.<\/span><\/p>\n

J.Clin.Oncol\u00a0 \u00a0 \u00a02011,29, e113-115<\/span><\/h4>\n

Tsuguo Iwatani, Hidetaka Kawabata, Daishu Miura, Yasunori Ota, Kenichi Ohashi<\/span>
\nComplete Spontaneous Regression of Primary Diffuse Large B-cell Lymphoma of the Breast<\/span><\/p>\n

N Engl J Med 2011;365:1056-7<\/span><\/h4>\n

Marie Hanaoka, Toshimi Takano, Hidetaka Kawabata (Comment on: N Engl J Med 2011; 364: 2381-2391)<\/span>
\nExemestane for Breast-Cancer Prevention.<\/span><\/p>\n

Breast Cancer, 2009, DOI 10.1007\/s12282-009-0149-1<\/span><\/h4>\n

Tsuguo Iwatani, Hidetaka Kawabata, Daishu Miura, Naoko Inoshita, Yasunori Ohta<\/span>
\nNodular fasciitis of the breast.<\/span><\/p>\n

Lancet,2001,358,1018<\/span><\/h4>\n

Hidetaka Kawabata, Takafumi Ueno<\/span>
\nScreening recommendation for women taking tamoxifen<\/span><\/p>\n

Lancet 2000,355,238<\/span><\/h4>\n

Takafumi Ueno\u3001Hidetaka Kawabata<\/span>
\nTobacco and health care professionals in Japan<\/span><\/p>\n

Lancet 1999,354,1207<\/span><\/h4>\n

Hidetaka Kawabata\uff0cTakafumi Ueno<\/span>
\nEarly Lung Cancer Action Project.<\/span><\/p>\n

Lancet 1999,353,2077<\/span><\/h4>\n

Hidetaka Kawabata\uff0cTakafumi Ueno<\/span>
\nControversy over cancer chemotherapy in Japan<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Breast Cancer \u3000 2024 Mar;31(2;31(2):234-242. Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale Yosuke Aoyama\u00a01,\u00a0Eri Hoshino\u00a02,\u00a0Akihiko Shimomura\u00a03,\u00a0Chikako Shimizu\u00a03,\u00a0Tomoko Taniyama\u00a03,\u00a0Manami Tada\u00a04,\u00a0Nao Yoshida\u00a04,\u00a0Hitomi Sato\u00a05,\u00a0Kiyomi Nonogaki\u00a05,\u00a0Kazumasa Yamamoto\u00a05,\u00a0Taro Yamanaka\u00a05,\u00a0Rika Kizawa\u00a05,\u00a0Takeshi Yamaguchi\u00a05,\u00a0Kiyo Tanaka\u00a06,\u00a0Yoko Kobayashi\u00a06,\u00a0Nobuko Tamura\u00a06,\u00a0Yuko Tanabe\u00a05,\u00a0Yuji Miura\u00a05,\u00a0Yuichiro Kikawa\u00a04,\u00a0Juhee Cho\u00a07,\u00a0Hidetaka Kawabata\u00a06 Jpn J Clin Oncol. 2023 Jun 29;53(7):562-571 Effectiveness of PET\/CT and VATS for detecting and treating internal mammary lymph node metastasis: A case series Shun Kawaguchi1*, Nobuko Tamura1, Soichiro Suzuki2, Aya Nishikawa1, Akio Shibata1, Kiyo Tanaka1, Yoko Kobayashi1, Takuya Ogura1, Junichiro Sato3, Keiichi Kinowaki3, Masato Shiiba4, Makiko Ishihara4, Sakashi Fujimori2 and Hidetaka Kawabata1 Breast Cancer. 2023 Jul;30(4):637-646. High-Accuracy Prediction of Axillary Lymph Node Metastas\u30fb\u30fb\u30fb<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5","post","type-post","status-publish","format-standard","hentry","category-achievement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/posts\/5"}],"collection":[{"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/comments?post=5"}],"version-history":[{"count":69,"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/posts\/5\/revisions"}],"predecessor-version":[{"id":566,"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/posts\/5\/revisions\/566"}],"wp:attachment":[{"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/media?parent=5"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/categories?post=5"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.tokyo-breast-clinic.jp\/doctor\/wp-json\/wp\/v2\/tags?post=5"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}